Giovanni Marconi

33PUBLICATIONS
187CO-AUTHORS
Gene and molecular therapyHaematological tumoursGene expression (incl. microarray and other genome-wide approaches)Cardiology (incl. cardiovascular diseases)Liquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Jul 02, 2026
Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

|Feb 11, 2026
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Naveen Pemmaraju, Giovanni Marconi, Pau Montesinos

|Jan 29, 2026
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia.

Diyanath Ranasinghe, Wei-Yu Lin, Sarah E Fordham

|Jan 13, 2026
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

Calogero Vetro, Irene Azzali, Elisabetta Petracci

|Sep 24, 2025
Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.

Fabio Guolo, Luana Fianchi, Maria Paola Martelli

|Mar 30, 2025
Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting.

Jacopo Nanni, Irene Azzali, Cristina Papayannidis

Pageof 6

Frequent Collaborators

8 joint publications

Cristina Papayannidis

6 joint publications

Fabio Guolo

6 joint publications

Michela Rondoni

6 joint publications

Giorgia Simonetti